Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03306199 · ClinicalTrials.gov registry record
TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
A clinical trial of Peripheral Arterial Disease, sponsored by Spectranetics Corporation.
- Completed
- Registry status
- 82
- Enrollment target
- 1
- Study location
NCT03306199 is a study of Peripheral Arterial Disease that has completed, run by Spectranetics Corporation. The registered enrollment target is 82 participants, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03306199, a study of Peripheral Arterial Disease, has completed, sponsored by Spectranetics Corporation.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).
Conditions Studied
Interventions
- DEVICE Laser Atherectomy
Study Locations (1)
Louisiana
- Cardiovascular Institute of the South - Houma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2018-06-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03306199
The ClinicalTrials.gov registry entry for NCT03306199 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower). The listed sponsor is Spectranetics Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Laser Atherectomy is the first listed.
NCT03306199 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT03306199 about?
NCT03306199 is a clinical study titled "TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions". A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).
What is the current status of trial NCT03306199?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2017-10-03. Estimated completion is 2018-06-05.
What conditions does trial NCT03306199 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT03306199?
The interventions under investigation include: Laser Atherectomy (DEVICE).
Who is sponsoring clinical trial NCT03306199?
This trial is sponsored by Spectranetics Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03306199 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.